229 related articles for article (PubMed ID: 11391724)
41. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
[TBL] [Abstract][Full Text] [Related]
42. [Idiopathic thrombocytopenic purpura associated with mantle cell lymphoma showing an increase in the platelet count receiving anti-CD20 antibody rituximab].
Kawachi Y; Ide M; Uchida T; Setsu K
Rinsho Ketsueki; 2003 Jan; 44(1):31-3. PubMed ID: 12649836
[TBL] [Abstract][Full Text] [Related]
43. Management of idiopathic thrombocytopenic purpura in elderly patients.
Andrès E; Daou S; Zimmer J; Federici L; Maloisel F
Eur J Haematol; 2007 Feb; 78(2):175. PubMed ID: 17313565
[No Abstract] [Full Text] [Related]
44. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Collins-Burow B; Santos ES
Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
[TBL] [Abstract][Full Text] [Related]
45. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
46. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
[TBL] [Abstract][Full Text] [Related]
47. [Monoclonal antibody therapy with mabtera of patients with b-cell low grade non-Hodgkin's lymphoma].
Karchenko VP; Voznyĭ EK; Belonogov AV; Bozhenko VK; Olfer'ev MA; Galil-Ogly GA
Vopr Onkol; 2005; 51(1):60-5. PubMed ID: 15909809
[TBL] [Abstract][Full Text] [Related]
48. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
[TBL] [Abstract][Full Text] [Related]
49. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.
Roguedas AM; Watier H; Paintaud G; de Muret A; Vaillant L; Machet L
Br J Dermatol; 2005 Mar; 152(3):541-4. PubMed ID: 15787825
[TBL] [Abstract][Full Text] [Related]
50. Recurrent immune thrombocytopenic purpura in children.
Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
Pediatr Hematol Oncol; 2006 Dec; 23(8):677-82. PubMed ID: 17065144
[TBL] [Abstract][Full Text] [Related]
51. Does rituximab aggravate pre-existing hypogammaglobulinaemia?
Diwakar L; Gorrie S; Richter A; Chapman O; Dhillon P; Al-Ghanmi F; Noorani S; Krishna MT; Huissoon A
J Clin Pathol; 2010 Mar; 63(3):275-7. PubMed ID: 20203231
[TBL] [Abstract][Full Text] [Related]
52. Idiopathic thrombocytopenic purpura in Hodgkin's lymphoma.
Patra SP; Mukherjee C
J Indian Med Assoc; 1995 Sep; 93(9):356-7. PubMed ID: 8648159
[No Abstract] [Full Text] [Related]
53. The role of the anti-CD20 antibody rituximab in hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.
Naparstek E
Curr Hematol Rep; 2005 Jul; 4(4):276-83. PubMed ID: 16009042
[TBL] [Abstract][Full Text] [Related]
54. Splenectomy results in patients with idiopathic thrombocytopenic purpura: 10 years of experience in Turgut Ozal Medical Center.
Ismet A; Irfan K; Emin K; AlI EM; Ramazan U; Mustafa B; Onur O
Clin Lab Haematol; 2004 Jun; 26(3):211-4. PubMed ID: 15163320
[TBL] [Abstract][Full Text] [Related]
55. Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment?
Clavio M; Quintino S; Venturino C; Ballerini F; Varaldo R; Gatto S; Galbusera V; Garrone A; Grasso R; Canepa L; Miglino M; Pierri I; Gobbi M
J Exp Clin Cancer Res; 2001 Sep; 20(3):351-8. PubMed ID: 11718214
[TBL] [Abstract][Full Text] [Related]
56. Antibody therapy for non-Hodgkin's lymphoma.
Ansell SM
Curr Opin Mol Ther; 2004 Apr; 6(2):175-81. PubMed ID: 15195930
[TBL] [Abstract][Full Text] [Related]
57. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
[TBL] [Abstract][Full Text] [Related]
58. CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma.
van Meerten T; Hagenbeek A
Neth J Med; 2009; 67(7):251-9. PubMed ID: 19687518
[TBL] [Abstract][Full Text] [Related]
59. Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma.
Protheroe A; Edwards JC; Simmons A; Maclennan K; Selby P
Rheumatology (Oxford); 1999 Nov; 38(11):1150-2. PubMed ID: 10556272
[TBL] [Abstract][Full Text] [Related]
60. Loss of CD20 expression in relapsed lymphomas after rituximab therapy.
Haidar JH; Shamseddine A; Salem Z; Mrad YA; Nasr MR; Zaatari G; Bazarbachi A
Eur J Haematol; 2003 May; 70(5):330-2. PubMed ID: 12694172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]